当前位置: 首页 >> 检索结果
81. Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy.
作者: Bin Zhang.;Maurice Enriquez-Sarano.;Hartzell V Schaff.;Hector I Michelena.;Carolyn M Roos.;Michael A Hagler.;Heyu Zhang.;Grace Casaclang-Verzosa.;Runqing Huang.;Anna Bartoo.;Sushant Ranadive.;Michael J Joyner.;Sorin Pislaru.;Vuyisile T Nkomo.;Walter K Kremers.;Philip A Araoz.;Gurpreet Singh.;Michael A Walters.;Jon Hawkinson.;Kevin Y Cunningham.;Jaeyun Sung.;Brandon Dunagan.;Zi Ye.;Jordan D Miller.
来源: Circulation. 2025年151卷13期913-930页
Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS.
82. Intravascular Imaging Predictors Associated With Cardiovascular Events After Complex PCIs.
作者: Joo Myung Lee.;Sang Yoon Lee.;Woochan Kwon.;Seung-Jae Lee.;Jong-Young Lee.;Seung Hun Lee.;Doosup Shin.;Sang Yeub Lee.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Ki Hong Choi.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.; .
来源: Circ Cardiovasc Interv. 2025年18卷2期e014920页
Intravascular imaging-guided percutaneous coronary intervention (PCI) has been shown to improve clinical outcomes in patients with complex coronary artery lesions compared with angiography-guided PCI. However, the prognostic impact of suboptimal findings on intravascular imaging such as stent underexpansion, malapposition, or dissection is unclear in the era of contemporary drug-eluting stents.
83. Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.
作者: Christian Gerges.;Mitja Jevnikar.;Philippe Brenot.;Laurent Savale.;Antoine Beurnier.;Hélène Bouvaist.;Olivier Sitbon.;Elie Fadel.;Athénaïs Boucly.;Denis Chemla.;Gérald Simonneau.;Marc Humbert.;David Montani.;Xavier Jaïs.; .
来源: Circ Cardiovasc Interv. 2025年18卷2期e014785页
Riociguat and balloon pulmonary angioplasty (BPA) improve hemodynamics in inoperable chronic thromboembolic pulmonary hypertension. Importantly, comparative effects of riociguat and BPA on different components of right ventricular (RV) afterload and function remain not fully elucidated.
84. Stepwise Provisional Versus Systematic Dual-Stent Strategies for Treatment of True Left Main Coronary Bifurcation Lesions.
作者: Sandeep Arunothayaraj.;Mohaned Egred.;Adrian P Banning.;Philippe Brunel.;Miroslaw Ferenc.;Thomas Hovasse.;Adrian Wlodarczak.;Manuel Pan.;Thomas Schmitz.;Marc Silvestri.;Andreis Erglis.;Evgeny Kretov.;Jens Flensted Lassen.;Alaide Chieffo.;Thierry Lefèvre.;Francesco Burzotta.;James Cockburn.;Olivier Darremont.;Goran Stankovic.;Marie-Claude Morice.;Yves Louvard.;David Hildick-Smith.
来源: Circulation. 2025年151卷9期612-622页
The optimal coronary stenting technique for true left main bifurcation lesions is uncertain. EBC MAIN (European Bifurcation Club Left Main Trial) aimed to evaluate clinical outcomes of a stepwise provisional strategy compared with a systematic dual-stent approach.
85. Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome.
作者: Xavier Jeunemaitre.;Elie Mousseaux.;Michael Frank.;Salma Adham.;Francesca Pitocco.;Clarisse Billon.;Molka Ben Yakhlef.;Mohamed El Hachmi.;Alessandra Bura-Rivière.;François-Xavier Lapébie.;Claire Le Hello.;Damien Laneelle.;Christophe Seinturier.;Klaus Dieterich.;Marc Lambert.;Sophie Dupuis-Girod.;Stéphane Zuily.;Laurence Bal-Theoleyre.;Carine Boulon.;Pierrick Henneton.;Estelle Lu.;Nicolas Denarié.;Pierre Boutouyrie.;Tristan Mirault.;Gilles Chatellier.;Michel Azizi.
来源: Circulation. 2025年151卷10期686-695页
Vascular Ehlers-Danlos syndrome is a rare genetic disorder characterized by defective type III collagen and a high risk of arterial morbidity and mortality. Several cardiovascular drugs are used for treatment, including celiprolol, but no controlled trial in this condition has been conducted to date. We hypothesized the benefit of the addition of an angiotensin II receptor blocker.
86. First-In-Human Study of [64Cu]Cu-DOTATATE PET/CT in Infective Endocarditis: A Prospective Head-to-Head Comparison With [18F]FDG.
作者: Katra Hadji-Turdeghal.;Marie Øbro Fosbøl.;Philip Hasbak.;Johan Löfgren.;Ida Bull Rasmussen.;Henning Bundgaard.;Kasper Iversen.;Niels Eske Bruun.;Christian H Møller.;Christian Tuxen.;Helle Hjorth Johannesen.;Lars Køber.;Andreas Kjær.;Rasmus Sejersten Ripa.;Emil Loldrup Fosbøl.
来源: Circ Cardiovasc Imaging. 2025年18卷2期e017156页
Infective endocarditis (IE) can be challenging to diagnose. Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[18F]-fluoro-d-glucose ([18F]FDG) is recommended as a diagnostic tool in the guidelines, but holds limitations. The aim of this study was to compare the tracer uptake between the novel [64Cu]Cu-DOTATATE, which has low cardiac uptake and does not require fasting or dietary restrictions, and [18F]FDG in patients with IE and examine the sensitivity and specificity.
87. Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial.
作者: Derek S Chew.;Daniel B Mark.;Yanhong Li.;Michael G Nanna.;Michelle D Kelsey.;Melanie R Daniels.;Linda Davidson-Ray.;Khaula N Baloch.;Campbell Rogers.;Manesh R Patel.;Kevin J Anstrom.;Nick Curzen.;Sreekanth Vemulapalli.;Pamela S Douglas.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011008页
The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) demonstrated that a precision diagnostic strategy reduced the primary composite of death, nonfatal myocardial infarction, or catheterization without obstructive coronary artery disease by 65% in patients with nonacute chest pain compared with usual testing. Medical cost was a prespecified secondary end point.
88. Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial.
作者: Daniel B Mark.;Yanhong Li.;Michael G Nanna.;Michelle D Kelsey.;Melanie R Daniels.;Campbell Rogers.;Manesh R Patel.;Khaula N Baloch.;Benjamin J W Chow.;Kevin J Anstrom.;Sreekanth Vemulapalli.;Jonathan R Weir-McCall.;Gregg W Stone.;Derek S Chew.;Pamela S Douglas.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011414页
The PRECISE (Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization) trial compared an investigational precision diagnostic testing strategy (n=1057) with usual testing (n=1046) in patients with stable chest pain and suspected coronary artery disease. Quality of life (QOL) outcomes were a prespecified secondary end point.
89. Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis.
作者: W H Wilson Tang.;Yuxi Liu.;Javed Butler.;Stefano Del Prato.;Justin A Ezekowitz.;Nasrien E Ibrahim.;Carolyn S P Lam.;Thomas H Marwick.;Riccardo Perfetti.;Julio Rosenstock.;Scott D Solomon.;Faiez Zannad.;James L Januzzi.;Gregory D Lewis.
来源: Circ Heart Fail. 2025年18卷3期e012200页
Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary exercise characteristics of individuals with diabetic cardiomyopathy at high risk for overt HF.
90. Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial.
作者: Deborah M F van den Buijs.;Ella M Poels.;Endry Willems.;Daan Cottens.;Kevin Dotremont.;Karen De Leener.;Evelyne Meekers.;Bert Ferdinande.;Mathias Vrolix.;Joseph Dens.;Koen Ameloot.
来源: Circ Cardiovasc Interv. 2025年18卷2期e013584页
Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose.
91. Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial.
作者: Stefano Barco.;Houman Jalaie.;Tim Sebastian.;Simon Wolf.;Riccardo M Fumagalli.;Michael Lichtenberg.;Thomas Zeller.;Christian Erbel.;Oliver Schlager.;Nils Kucher.
来源: Circulation. 2025年151卷12期835-846页
In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within 6 months after stent placement for post-thrombotic syndrome.
92. Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.
作者: Kirstine Nørregaard Hansen.;Jens Trøan.;Akiko Maehara.;Manijeh Noori.;Mikkel Hougaard.;Julia Ellert-Gregersen.;Karsten Tange Veien.;Anders Junker.;Henrik Steen Hansen.;Jens Flensted Lassen.;Lisette Okkels Jensen.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014665页
Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound.
93. Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG.
作者: Daimy M M Dillen.;Hisao Otsuki.;Kuniaki Takahashi.;Yuhei Kobayashi.;Zsolt Piroth.;Nicolas Noiseux.;Badih El Nakadi.;Gintaras Kalinauskas.;Laszlo Szekely.;Giedrius Davidavičius.;Koen Teeuwen.;Pim A L Tonino.;Nico H J Pijls.;Bernard De Bruyne.;William F Fearon.;Frederik M Zimmermann.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014610页
In the era of first-generation drug-eluting stents and angiography-guided percutaneous coronary intervention (PCI), the presence of a bifurcation lesion was associated with adverse outcomes after PCI. In contrast, the presence of a bifurcation lesion had no impact on outcomes following coronary artery bypass grafting (CABG). Therefore, the presence of a coronary bifurcation lesion requires special attention when choosing between CABG and PCI. The aim of this study is to assess whether the presence of a bifurcation lesion still influences clinical outcomes after contemporary PCI using second-generation drug-eluting stent and fractional flow reserve (FFR) guidance versus CABG.
94. Cryoballoon Pulmonary Vein Isolation With Versus Without Additional Right Atrial Linear Ablation for Persistent Atrial Fibrillation: The CRALAL Randomized Clinical Trial.
作者: Daehoon Kim.;Hee Tae Yu.;Jaemin Shim.;Junbeom Park.;Yong-Soo Baek.;Sang Won Park.;Dae-Kyeong Kim.;Young-Ah Park.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hui-Nam Pak.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e013408页
Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).
95. Nurse-Led Multicomponent Behavioral Activation Intervention for Patients With Atrial Fibrillation: A Randomized Controlled Trial.
Patients with atrial fibrillation (AF) are often ill-equipped for shared decision-making. This study investigated the effects of a patient empowerment care model on patient-reported health outcomes and treatment decision-making in patients with AF.
96. Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.
作者: Kevin R Bainey.;Robert C Welsh.;Yinggan Zheng.;Alexandra Arias-Mendoza.;Arsen D Ristic.;Oleg V Averkov.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Tracy Temple.;Eric Ly.;Kris Bogaerts.;Peter R Sinnaeve.;Thierry Danays.;Cynthia M Westerhout.;Frans Van de Werf.;Paul W Armstrong.; .
来源: Circ Cardiovasc Interv. 2024年17卷12期e014251页
In STREAM-1 (Strategic Reperfusion Early After Myocardial Infarction), excess intracranial hemorrhage occurred in patients aged ≥75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, whereas no further intracranial hemorrhage occurred after halving the tenecteplase dose. In STREAM-2 (Second Strategic Reperfusion Early After Myocardial Infarction), half-dose tenecteplase was an effective and safe pharmaco-invasive strategy in older patients with ST-segment-elevation myocardial infarction presenting within <3 hours, compared with primary percutaneous coronary intervention (PCI). We prespecified evaluating the efficacy and safety of a half-dose versus full-dose pharmaco-invasive strategy and compared the half-dose pharmaco-invasive strategy to primary PCI in patients aged ≥75 years.
97. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
作者: Harmony R Reynolds.;Courtney B Page.;Leslee J Shaw.;Daniel S Berman.;Bernard R Chaitman.;Michael H Picard.;Raymond Y Kwong.;James K Min.;Jonathon Leipsic.;G B John Mancini.;Matthew J Budoff.;Cameron J Hague.;Roxy Senior.;Hanna Szwed.;Balram Bhargava.;Jelena Celutkiene.;Milind Gadkari.;Kevin R Bainey.;Rolf Doerr.;Ruben B Ramos.;Peter Ong.;Sudhir R Naik.;Philippe Gabriel Steg.;Kaatje Goetschalckx.;Benjamin J W Chow.;Marielle Scherrer-Crosbie.;Lawrence Phillips.;Daniel B Mark.;John A Spertus.;Karen P Alexander.;Sean M O'Brien.;William E Boden.;Sripal Bangalore.;Gregg W Stone.;David J Maron.;Judith S Hochman.; .
来源: Circ Cardiovasc Interv. 2024年17卷12期e013743页
The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of stress achieved, type of testing used, presence and extent of prior infarction, collateral blood flow, plaque characteristics, microvascular disease, coronary vasomotor tone, and genetic factors. Among chronic coronary disease participants with site-determined moderate or severe ischemia, we investigated associations between ischemia severity on stress testing and the extent of CAD on coronary computed tomography angiography.
98. Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial.
作者: Víctor Castro-Urda.;Melodie Segura-Dominguez.;Diego Jiménez-Sánchez.;Cristina Aguilera-Agudo.;Paula Vela-Martín.;Alvaro Lorente-Ros.;Daniel García-Rodriguez.;David Sánchez-Ortiz.;Chinh Pham-Trung.;Eusebio García-Izquierdo.;Susana Mingo-Santos.;Jorge Toquero-Ramos.;Ignacio Fernández-Lozano.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e012917页
Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development.
99. Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN Trial.
作者: Louise R A Olde Nordkamp.;Shari Pepplinkhuizen.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El-Chami.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Anne-Floor B E Quast.;Willeke van der Stuijt.;Lonneke Smeding.;Jolien A de Veld.;Jan G P Tijssen.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovsky.;Ralf Surber.;Gaurav A Upadhyay.;Raul Weiss.;Anouk de Weger.;Arthur A M Wilde.;Reinoud E Knops.; .
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e012836页
Inappropriate therapy (IAT) is an undesirable side effect of implantable cardiac defibrillator (ICD) therapy. Early studies with the subcutaneous ICD (S-ICD) showed relatively high inappropriate shock (IAS) rates. The PRAETORIAN (Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) trial demonstrated that the S-ICD is noninferior to the transvenous ICD (TV-ICD) with regard to the combined end point of IAS and complications. This secondary analyses evaluates all IAT in the PRAETORIAN trial.
100. Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).
作者: Neal W Dickert.;Candace D Speight.;Madeline Balser.;Henry Biermann.;J Kelly Davis.;Scott D Halpern.;Yi-An Ko.;Advaita Krishnan.;Daniel D Matlock.;Andrea R Mitchell.;Miranda A Moore.;Sarah C Montembeau.;Alanna A Morris.;Kathleen Noonan.;Birju R Rao.;Laura D Scherer.;Caroline E Sloan.;Peter A Ubel.;Larry A Allen.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷1期e011273页
Guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction can entail high out-of-pocket (OOP) costs, prompting concerns about financial toxicity and access. OOP costs are generally unavailable during encounters. This trial assessed the impact of providing patient-specific OOP costs to patients and clinicians.
|